Sugi Predict

Sugi Predict / Compounds / SCHEMBL7181822

SCHEMBL7181822

SCHEMBL7181822

COc1cc(Br)c(OC)c(C(=O)P(=O)(C(=O)c2c(C)cc(C)c(C)c2C)c2ccccc2)c1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 3/20 0.39
▸ LMNA P02545 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ MAPT P10636 2/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ ATM Q13315 1/20 0.35
▸ ABCG2 Q9UNQ0 1/20 0.35
▸ HTT P42858 2/20 0.34
▸ TSHR P16473 1/20 0.34
▸ APOBEC3A P31941 1/20 0.34
▸ APOBEC3G Q9HC16 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ TUBB4A P04350 1/20 0.34
▸ TUBB P07437 1/20 0.34
▸ TUBA3C P0DPH7 1/20 0.34
▸ TUBA1B P68363 1/20 0.34
▸ TUBA4A P68366 1/20 0.34
▸ TUBB4B P68371 1/20 0.34
▸ TUBB3 Q13509 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7183219 0.91 HPGD (0.37) HPGDLMNASMN1; SMN2MAPTKMT2A
SCHEMBL7187379 0.89 LMNA (0.41) HPGDLMNASMN1; SMN2MAPTKMT2A
SCHEMBL7190080 0.88 POLB (0.41) HPGDLMNASMN1; SMN2MAPTKMT2A
SCHEMBL7185490 0.88 LMNA (0.41) HPGDLMNASMN1; SMN2MAPTKMT2A
SCHEMBL7189605 0.86 TDP1 (0.36) HPGDLMNASMN1; SMN2MAPTKMT2A
SCHEMBL7181469 0.86 ABCB1 (0.34) HPGDLMNAMAPTKMT2AMEN1
SCHEMBL7187083 0.86 SMN1; SMN2 (0.39) HPGDLMNASMN1; SMN2MAPTKMT2A
SCHEMBL7180966 0.85 LMNA (0.43) HPGDLMNASMN1; SMN2MAPTKMT2A
SCHEMBL7181816 0.84 ATM (0.41) HPGDLMNASMN1; SMN2MAPTKMT2A
SCHEMBL7183742 0.83 HPGD (0.41) HPGDLMNASMN1; SMN2MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 HPGD 3983/4885LMNA 3241/4885SMN1; SMN2 2939/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 HPGD 4041/4885LMNA 3247/4885SMN1; SMN2 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.